Personalized treatments for depressive symptoms in patients with advanced heart failure: A pragmatic randomized controlled trial

IsHak, Waguih William and Korouri, Samuel and Darwish, Tarneem and Vanle, Brigitte and Dang, Jonathan and Edwards, Gabriel and Black, Jeanne T. and Aronow, Harriet and Kimchi, Asher and Spiegel, Brennan and Hedrick, Rebecca and Chernoff, Robert and Diniz, Marcio A. and Mirocha, James and Manoukian, Vicki and Harold, John and Ong, Michael K. and Wells, Kenneth and Hamilton, Michele and Danovitch, Itai and Moitra, Ethan (2021) Personalized treatments for depressive symptoms in patients with advanced heart failure: A pragmatic randomized controlled trial. PLOS ONE, 16 (1). e0244453. ISSN 1932-6203

[thumbnail of journal.pone.0244453.pdf] Text
journal.pone.0244453.pdf - Published Version

Download (859kB)

Abstract

Objectives
Heart Failure is a chronic syndrome affecting over 5.7 million in the US and 26 million adults worldwide with nearly 50% experiencing depressive symptoms. The objective of the study is to compare the effects of two evidence-based treatment options for adult patients with depression and advanced heart failure, on depressive symptom severity, physical and mental health related quality of life (HRQoL), heart-failure specific quality of life, caregiver burden, morbidity, and mortality at 3, 6 and 12-months.

Methods
Trial design. Pragmatic, randomized, comparative effectiveness trial.

Interventions. The treatment interventions are: (1) Behavioral Activation (BA), a patient-centered psychotherapy which emphasizes engagement in enjoyable and valued personalized activities as selected by the patient; or (2) Antidepressant Medication Management administered using the collaborative care model (MEDS).

Participants. Adults aged 18 and over with advanced heart failure (defined as New York Heart Association (NYHA) Class II, III, and IV) and depression (defined as a score of 10 or above on the PHQ-9 and confirmed by the MINI International Neuropsychiatric Interview for the DSM-5) selected from all patients at Cedars-Sinai Medical Center who are admitted with heart failure and all patients presenting to the outpatient programs of the Smidt Heart Institute at Cedars-Sinai Medical Center. We plan to randomize 416 patients to BA or MEDS, with an estimated 28% loss to follow-up/inability to collect follow-up data. Thus, we plan to include 150 in each group for a total of 300 participants from which data after randomization will be collected and analyzed.

Conclusions
The current trial is the first to compare the impact of BA and MEDS on depressive symptoms, quality of life, caregiver burden, morbidity, and mortality in patients with depression and advanced heart failure. The trial will provide novel results that will be disseminated and implemented into a wide range of current practice settings.

Item Type: Article
Subjects: European Repository > Medical Science
Depositing User: Managing Editor
Date Deposited: 02 Dec 2022 04:01
Last Modified: 06 May 2024 05:45
URI: http://go7publish.com/id/eprint/672

Actions (login required)

View Item
View Item